Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Videos

First-Line Ibrutinib Demonstrates Long-Term Efficacy in TP53-Mutated CLL

 

John Allan, MD, Weill Cornell Medicine, New York, New York, discusses results from analysis exploring the long-term efficacy of first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) and TP53 mutations.

These results were presented at the virtual American Society of Hematology (ASH) 62nd Annual Meeting.


Advertisement

Advertisement

Advertisement